Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

NCT03170180 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms

Interventions

DRUG: Sunitinib
DRUG: Gefitinib
DRUG: Imatinib

Sponsor

Samsung Medical Center